Oxcarbazepine

Limits on what this shows

• Key negative/null: The same reference explicitly separates oxcarbazepine from valproate's well-characterized, more severe mitochondrial toxicity, an implicit bound on this entry.
• At-risk subgroups: Patients with pre-existing mitochondrial disease, per the reference's overall clinical framing.
• Counter-evidence on record: None specific to oxcarbazepine identified.

Regulatory status

Not addressed in the label.

Population evidence

Finsterer and Zarrouk Mahjoub, Expert Opinion on Drug Metabolism and Toxicology, 2012, an established pharmacology reference on AEDs and mitochondrial disorders, names oxcarbazepine specifically in a list of drugs that "may affect the mitochondrial metabolism" (Tier B, drug named, no quantification).

Mechanism

Not specified for oxcarbazepine. The best-established AED mitochondrial mechanism is valproate's carnitine-dependent interference with beta-oxidation, a pathway that does not apply to oxcarbazepine's chemistry.

Counter-evidence held on record

This is a general, unquantified listing, not evidence of clinically meaningful mitochondrial toxicity from oxcarbazepine, and should not be read as comparable in severity to valproate's mitochondrial risk.

Limits on what this shows

• Key negative/null: Not retrievable; neither abstract could be accessed during this review.
• At-risk subgroups: Not determinable from available data.
• Counter-evidence on record: Not retrievable; disclosed as a genuine access limitation, not folded into a higher-confidence grade.

Regulatory status

Not addressed in the label.

Population evidence

Bolayir et al., Methods and Findings in Experimental and Clinical Pharmacology, 2004, human epileptic patients treated with oxcarbazepine, oxidative stress parameters measured per the title (Tier A: drug in cohort, direct measurement). Agarwal et al., Seizure, 2011, PTZ-kindled mice dosed with oxcarbazepine among other AEDs, oxidative stress markers measured (Tier B, animal, drug in cohort).

Mechanism

Not confirmed from retrievable metadata. Oxidative stress in epilepsy is plausible in either direction: seizures themselves generate oxidative stress, and AEDs are variably reported as pro-oxidant or protective depending on the compound; no oxcarbazepine-specific mechanism could be confirmed here.

Counter-evidence held on record

This entry reflects that dedicated, drug-specific research exists, not that a specific harmful or protective effect is confirmed. Treat as an open question pending full-text verification, not as evidence that oxcarbazepine requires antioxidant supplementation.

Limits on what this shows

• Key negative/null: None identified; the abstract does not report a null comparison isolating oxcarbazepine from its two combination partners.
• At-risk subgroups: Pediatric patients on multi-drug regimens that include oxcarbazepine, per this cohort; not established for oxcarbazepine monotherapy or adult patients.
• Counter-evidence on record: None identified. This entry is deliberately not built on the class-level 1983 and 2003 hypercupraemia/ceruloplasmin literature cited in the companion carbamazepine dossier, both of which were confirmed, by direct record check, to have studied carbamazepine, phenytoin, phenobarbital, and valproic acid but not oxcarbazepine; that class literature is background only and is not the evidentiary basis for this grade.

Regulatory status

Not addressed in the FDA label.

Population evidence

Bakri AH, Meki AMA, Nassar AY, Hassan MH, Ellisy RAM, Radwan E, Ameen HH, Nasser SA, Abd-Elmawgood EA. Clin Lab, 2023 (PMID 37948472), "Validity of Serum Zinc/Copper Ratio as a Potential Novel Biomarker in Childhood Epilepsy." 100 epileptic children (50 pharmacoresistant, 50 pharmacoresponsive) versus age- and gender-matched healthy controls; drugs studied were levetiracetam, sodium valproate, and oxcarbazepine, alone and in combination. Children treated with the levetiracetam/sodium valproate/oxcarbazepine triple combination had a significantly higher zinc/copper ratio than those on levetiracetam alone or levetiracetam plus sodium valproate (p less than 0.05 for both comparisons). Oxcarbazepine appears in this cohort only as part of that triple combination; no oxcarbazepine-monotherapy arm is described. Epileptic children overall had a significantly lower zinc/copper ratio than healthy controls, with 64 percent sensitivity and 85 percent specificity at a cutoff of 1.118 for distinguishing epilepsy from controls.

Mechanism

Not established for oxcarbazepine specifically. A ratio finding does not by itself indicate whether copper, zinc, or both moved, or in which direction each moved; raw serum copper and zinc concentrations were not available in the accessible abstract.

Counter-evidence held on record

Direction is not established: this is not confirmed evidence of either copper deficiency or copper excess for oxcarbazepine specifically. No copper dose is given because none applies; an abnormal copper or ceruloplasmin result on this drug calls for medical evaluation, not self-directed copper supplementation or avoidance.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence found to support even a yellow grade, and no circulating consumer claim was found to rebut as white. Re-confirmed on this repair pass with a fresh, genuine multi-channel search; Copper, Gut microbiome risk, and ATP production, previously grouped with Iron as ungraded, were each upgraded this pass (see above) and Iron alone remains ungraded.

Channels tried

This repair pass: PubMed search-listing pages queried as "oxcarbazepine iron ferritin" (zero results) and "oxcarbazepine iron" (3 results returned: a restless-legs-syndrome review naming oxcarbazepine only in a drug list with no iron-mechanism content, an unrelated adjunctive-therapy trial, and an unrelated analytical-chemistry assay method; none support a copper or iron claim for this drug). Crossref API query ("oxcarbazepine iron deficiency anemia") returned successfully, all results were general iron-deficiency-anemia reference chapters with no antiepileptic drug named. Europe PMC and the OpenAlex search endpoint were both rate-limited (HTTP 429) on every attempt this pass, consistent with the organization-level access constraint noted in the original review; OpenAlex per-record lookups worked where a specific candidate PMID was already known, but no Iron-specific candidate PMID was surfaced to look up this way. DailyMed label re-checked, no iron or hematinic mention. The consumer circulating-claim sources already in this dossier's Sources list (Drugs.com, U.S. Pharmacist continuing-education review) were reviewed for this pass and, as previously found, surface a sodium/hyponatremia warning only, with no iron claim to rebut.

Assessment

Genuine gap, not a tooling artifact: the successful Crossref and PubMed queries this pass returned real, on-topic results and none supported any drug-specific or class-level iron connection. This mirrors the companion carbamazepine dossier, where the same drug-mugging-style "iron deficiency" claim was traced to a conflation with that drug's labeled marrow-suppression risk and explicitly rebutted as white; oxcarbazepine's own rare postmarketing aplastic anemia/pancytopenia signal (see Oxygen delivery/utilization, orange, above) is the same category of idiosyncratic marrow toxicity, not iron-deficiency anemia, and is not counted as iron evidence here. Europe PMC and OpenAlex search access remain blocked at an apparent organization level; a future revision with restored access to those two channels specifically is the most useful next re-check.

Limits on what this shows

• Key negative/null: Not retrievable; the specific before-versus-after-treatment comparison in Gong 2022, which would most directly test a drug effect independent of baseline disease status, could not be confirmed from the accessible abstract.
• At-risk subgroups: Pediatric, newly diagnosed focal epilepsy, per the one drug-specific cohort located; not established for adults or longer-term use.
• Counter-evidence on record: Per Hard Rule 6, confounding by indication is presumed until excluded: epilepsy itself, independent of any specific drug, has its own reported microbiome associations in the literature, and this review could not confirm from the accessible text that the Gong 2022 finding survives that presumption.

Regulatory status

Not addressed in the label.

Population evidence

Gong SZ, Qiu J, Wu LW, Tan LH. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics), 2022 (PMID 35351260, DOI 10.7499/j.issn.1008-8830.2109134). Ten children with newly diagnosed focal epilepsy, all treated with oxcarbazepine alone (monotherapy, Tier A by cohort/design), versus 14 age-matched healthy controls; fecal 16S rDNA sequencing performed before and three months after treatment start. The accessible abstract states a significant difference (p less than 0.05) in intestinal flora between the epilepsy group and healthy controls; it does not, in the portion this review could access, separately state whether the specific pre-treatment-to-post-treatment comparison (the arm that would isolate a drug effect from baseline disease-associated dysbiosis) reached significance or in which direction, and specific bacterial taxa were not retrievable. Full text was blocked by a bot-verification page on both the PMC and HAL mirrors attempted. Class-level, non-oxcarbazepine-specific corroboration: Ilhan ZE, Brochard V, Lapaque N, Auvin S, Lepage P. Neurobiol Dis, 2022 (PMID 35183703), an in vitro screen naming carbamazepine, lamotrigine, and topiramate (not oxcarbazepine, per the accessible abstract and full-text access attempts, both blocked) as reducing growth of gut bacterial strains. Dop C, Auvin S, Mondot S, Lepage P, Ilhan ZE. ISME Commun, 2024 (PMID 39526134, open access), a longitudinal fecal-microcosm study confirming only carbamazepine, valproic acid, and levetiracetam were tested, oxcarbazepine confirmed absent from this cohort. Zammar K, AbuAlrob MA, Ali M, Lattanzi S, Mesraoua B. Epilepsia Open, 2026 (PMID 42541365), a narrative review naming oxcarbazepine among ASMs subject to microbiome-mediated biotransformation and a proposed bidirectional dysbiosis-pharmacoresistance cycle, without oxcarbazepine-specific primary data (Tier C for the drug-affects-microbiome direction specifically).

Mechanism

Not established specifically for oxcarbazepine. Proposed at the class level: direct antimicrobial-adjacent activity of some AEDs on gut bacterial growth (demonstrated for carbamazepine in vitro) and microbiome-mediated biotransformation of ASMs including oxcarbazepine (Zammar 2026, mechanism named in the reverse direction, microbiome acting on the drug, not confirmed as drug-on-microbiome for oxcarbazepine specifically).

Counter-evidence held on record

Not a basis for probiotic or other supplement recommendations. This entry reflects that a drug-specific study exists and reported a significant flora difference, not that oxcarbazepine has been confirmed to cause gut dysbiosis independent of the underlying epilepsy.

Limits on what this shows

• Key negative/null: None identified; rarity itself, not a null study, is the main bound on this entry.
• At-risk subgroups: Not defined by dose or duration in the label; treated as idiosyncratic rather than dose-dependent.
• Counter-evidence on record: None identified.

Regulatory status

FDA label, postmarketing experience, lists aplastic anemia, thrombocytopenia, pancytopenia, agranulocytosis, and leukopenia as rare events, and recommends considering discontinuation if they develop.

Population evidence

Postmarketing spontaneous reports only (label). Jang, Korean Journal of Pediatrics, 2019, a drug-specific editorial, argues for active hematologic monitoring in oxcarbazepine-treated patients, indicating this is a recognized, ongoing clinical concern specific to this drug; full text could not be retrieved during this review (see Sources).

Mechanism

Not nutrient-related. Idiosyncratic or immune-mediated bone marrow suppression is the presumed mechanism for AED-associated blood dyscrasias generally; no iron, B12, or copper deficiency pathway is implicated.

Counter-evidence held on record

A falling hemoglobin, unusual bruising, or recurrent infection on this drug warrants a CBC and prompt medical evaluation, not iron or B12 supplementation. This is not a deficiency state, and supplementation would not address it.

Limits on what this shows

• Key negative/null: Energy charge, a ratio reflecting the cell's adenylate pool balance rather than absolute ATP, was not altered despite the absolute ATP decrease; this tempers the finding and is reported here rather than omitted. Carbamazepine, tested in the same experiment at the same concentration, did not significantly lower ATP, a direct within-study negative comparator.
• At-risk subgroups: Not established for human use; this is a single in vitro concentration (300 micromolar) in rodent neurons, not a human exposure level.
• Counter-evidence on record: None identified beyond the energy-charge null noted above. Cell-culture-only evidence is itself the reason this stays capped at yellow rather than advancing further.

Regulatory status

Not addressed in the label.

Population evidence

Araujo IM, Ambrosio AF, Leal EC, Verdasca MJ, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM. Epilepsia, 2004;45(12):1498-1505 (PMID 15571507, DOI 10.1111/j.0013-9580.2004.14104.x), "Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093" (Tier B, in vitro, oxcarbazepine directly tested, not merely named). Primary rat hippocampal neurons were exposed for 24 hours to 300 micromolar oxcarbazepine, carbamazepine, BIA 2-024, or BIA 2-093. Intracellular ATP was quantified by HPLC. Result, quoted from the abstract: "ATP levels were significantly decreased only in neurons treated with OXC, although the energy charge was not altered." Reactive oxygen species were also increased only with oxcarbazepine among the four compounds, and oxcarbazepine independently decreased mitochondrial membrane potential (Psi m). The paper's own conclusion states oxcarbazepine was more toxic than the other three compounds tested on every parameter assayed.

Mechanism

Named at the cellular level: oxcarbazepine exposure lowered mitochondrial membrane potential and raised reactive oxygen species alongside the ATP decrease, consistent with a mitochondrial bioenergetic disruption, though the paper does not identify which mitochondrial complex or step is affected.

Counter-evidence held on record

Cell-culture evidence at a single concentration, not a basis for any supplement, dosing, or "low energy" claim in humans. See Overlap map: this same source also reports oxidative-stress and mitochondrial-membrane-potential findings for oxcarbazepine that are directly relevant to, though not currently cited by, the Oxidative stress and Mitochondrial burden entries above, which rest on different sources.